Chemical Structure (Eysuvis 01)
Eysuvis Suspension/ Drops
Product Images NDC 71571-333
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Eysuvis (NDC 71571-333). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alcon Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Eysuvis 02)
This appears to be a table summarizing some numerical data from four studies related to vehicle and EVSUVIS differences. Each study seems to have multiple visits with a certain number of participants (N) and a baseline value. Additionally, for each visit there are values for EVSUVIS, a difference value, and a confidence interval. More information is needed to provide a more comprehensive description.*
Figure 2 (Eysuvis 03)
Figure A (Eysuvis 04)
Figure B (Eysuvis 05)
Figure C (Eysuvis 06)
Figure D (Eysuvis 07)
Figure E (Eysuvis 08)
Figure F (Eysuvis 09)
Bottle Label (Eysuvis 10)
This is a description of a prescription medication with the NDC number 71571-333-83 called "EYSuvIS". It is an ophthalmic suspension containing 0.25% of the active ingredient, ioteprednol etabonate. The medication comes in a sterile 8.3 mL container and is intended for topical application in the eye. The dosage information is included in the package insert. The medication is manufactured by Kala Pharmaceuticals in Watertown, MA.*
Carton Label (Eysuvis 11)
EYSUVIS™ Ophthalmic Suspension is a medication used for topical application in the eye. The active ingredient is loteprednol etabonate 2.5 mg (0.25%) and the inactive components include glycerin, sodium citrate dihydrate, sodium chloride, Poloxamer 407, edetate disodium dihydrate, citric acid, and water for injection. The medication is produced by Kala Pharmaceuticals Inc. and should be stored upright at 15°C to 25°C (59°F to 77°F). The tamper-evident overcap should be intact before use. The dosage details are present in the package insert.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
